The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10732 malaria professionals are enjoying the free benefits of MalariaWorld today

TMPRSS2

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2

January 20, 2021 - 07:00 -- Open Access
Author(s): 
Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M
Reference: 
PLoS Pathog. 2021 Jan 19;17(1):e1009212

Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies. However, human clinical trials of hydroxychloroquine failed to establish its usefulness as treatment for COVID-19. This compound is known to interfere with endosomal acidification necessary to the proteolytic activity of cathepsins. Following receptor binding and endocytosis, cathepsin L can cleave the SARS-CoV-1 and SARS-CoV-2 spike (S) proteins, thereby activating membrane fusion for cell entry.

Subscribe to RSS - TMPRSS2